By Fineline Cube 
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results, with sunvozertinib (Zegfrovy) generating RMB 576 million (USD 83.4 million) in revenue following an 85.21% year-over-year expansion. The company’s total sales reached RMB 801 million (USD 116 million), marking a 122.60% YOY increase, driven primarily by the inclusion of both commercialized products in China’s National Reimbursement Drug List (NRDL) for the first time in 2025.
Financial Performance Summary
| Metric | 2025 Result | YOY Change |
|---|---|---|
| Total Sales Revenue | RMB 801M (USD 116M) | +122.60% |
| Sunvozertinib Revenue | RMB 576M (USD 83.4M) | +85.21% |
| Golidocitinib Revenue | RMB 226M (USD 32.7M) | +359.32% |
| R&D Investment | RMB 856M (USD 124M) | +18.23% |
| Net Loss | RMB 764M (USD 111M) | N/A |
| Cash & Cash Equivalents | RMB 1.936B (USD 280M) | +130.5% vs. 2024 |
Product Portfolio Highlights
Sunvozertinib (Zegfrovy)
- Indication: Next-generation EGFR inhibitor for EGFR Exon20ins mutated non-small cell lung cancer
- China Approval: August 2023
- US FDA Approval: July 2025
- NRDL Inclusion: 2025 (first-time)
- Commercial Impact: Positioned for global market expansion following US regulatory milestone
Golidocitinib
- Mechanism: World’s first and only novel mechanism drug targeting the JAK/STAT pathway for PTCL (Peripheral T-cell Lymphoma)
- NRDL Inclusion: 2025 (first-time)
- Commercial Impact: Exceptional 359.32% YOY growth demonstrates strong market demand for innovative oncology therapies
Strategic Pipeline Overview
- Total Pipeline Assets: 7 products in development
- Commercialized Products: 2 (sunvozertinib and golidocitinib)
- NRDL Status: Both commercial products secured reimbursement coverage in 2025
- Global Expansion: Sunvozertinib’s FDA approval opens US market opportunity
- Financial Strength: Cash position more than doubled to RMB 1.936 billion, providing runway for continued R&D investment
Market Analysis & Outlook
| Factor | Implication |
|---|---|
| NRDL Inclusion | Immediate access to China’s 1.4 billion population through public insurance coverage |
| FDA Approval | Sunvozertinib becomes Dizal’s first globally approved product, enabling international partnerships |
| R&D Investment | Sustained 18.23% increase demonstrates commitment to innovation despite net losses |
| Cash Position | Strong liquidity supports pipeline advancement and potential business development activities |
The company’s strategic focus on innovative oncology assets with novel mechanisms has yielded significant commercial success. The simultaneous NRDL inclusion of both products in 2025 created immediate market access, while sunvozertinib’s FDA approval positions Dizal as an emerging global player in precision oncology.
Forward Guidance
- Revenue Trajectory: Expect continued strong growth in 2026 driven by full-year NRDL benefits and US market entry for sunvozertinib
- Pipeline Advancement: Robust cash position supports advancement of remaining 5 pipeline assets
- Global Strategy: Potential licensing partnerships for sunvozertinib in major international markets
- Profitability Path: Operating leverage from growing revenue base may improve path to profitability despite continued R&D investment
Forward‑Looking Statements
This brief contains forward-looking statements regarding Dizal Pharmaceutical’s financial performance, product commercialization, regulatory approvals, and business strategy. Actual results may differ materially due to regulatory, competitive, and market risks.-Fineline Info & Tech